User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 18 results.
    • Speech
    PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)
    Siena, S. Elez, E. Peeters, M. André, T. Van den Eynde, Marc[UCL] Ng, K. Cercek, A. Fountzilas, C. Sanchez, F. Hubbard, J. Wu, C. Tabernero, J. Kardosh, A. Saeed, A. Strickler, J. Bekaii-Saab, T. Stecher, M. Palanca-Wessels, M. Van Cutsem, E. (2021) ESMO World Congress on Gastrointestinal Cancer 2021 —
    • Journal article
    Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.
    Bourhis, Jean Stein, Alexander Paul de Boer, Jan Van den Eynde, Marc[UCL] Gold, Kathryn A Stintzing, Sebastian Becker, Jürgen C Moran, Michael Schroeder, Andreas Pennock, Gregory Salmio, Satu Esser, Regina Ciardiello, Fortunato (2021) Cancer treatment reviews — Vol. 97, p. 102172 [1-9] (2021)
    • Speech
    Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)—A proof of concept, open-label, nonrandomized phase IIa study.
    Van den Eynde, Marc[UCL] Huyghe, Nicolas De Cuyper, Astrid[UCL] Sinapi, Isabelle Ferrier, Marie Gilet, Mélanie Van Maanen, Aline[UCL] Castella, Marie-Laure[UCL] Galon, Jerome Carrasco, Javier (2021) 2021 Gastrointestinal Cancers Symposium —
    • Speech
    Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).
    Raghav, Kanwal Pratap Singh Yoshino, Takayuki Guimbaud, Rosine Chau, Ian Van den Eynde, Marc[UCL] Maurel, Joan Tie, Jeanne Kim, Tae Won Yeh, Kun-Huei Barrios, Daniel Kobayashi, Kojiro Bako, Emarjola Aregay, Mehreteab Meinhardt, Gerold Siena, Salvatore (2021) 2021 ASCO Annual Meeting I —
    • Speech
    Abstract CT192: Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer
    Ponz-Sarvisé, Mariano Élez, Elena Muñoz, Andrés Van den Eynde, Marc[UCL] Rampoldi, Antonio Gaetano Hendlisz, Alain Prenen, Hans Rodríguez, Mercedes Cano, María Teresa Chaney, Marya Escuin, Helena Pons, Vanesa Quintero, Marisol Cervantes, Andrés (2021) AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA —
    • Speech
    O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup
    Ajani, J. El Hajbi, F. Cunningham, D. Alsina, M. Thuss-Patience, P. Scagliotti, G. Van den Eynde, Marc[UCL] Rybkin, I. Shen, L. Kato, K. Kim, S. D’Alonzo, S. Yu, W. Tao, A. Van Cutsem, E. (2021) ESMO World Congress on Gastrointestinal Cancer 2021 —
    • Speech
    Prognostic value of baseline and early changes of circulating-free (cf) and circulating tumor (ct) DNA in the neoadjuvant (NA) setting of early stage colon cancer (CC).
    Bregni, Giacomo Senti, Chiara Vandeputte, Caroline Acedo Reina, Elena Gkolfakis, Paraskevas Van Laethem, Jean-Luc Vergauwe, Philippe Van den Eynde, Marc[UCL] Janssens, Jos Demolin, Gauthier Holbrechts, Stephane Clausse, Marylene De Grez, Thierry D'Hondt, Lionel A. Geboes, Karen Paula Besse-Hammer, Tatiana Rothe, Francoise Flamen, Patrick Hendlisz, Alain Sclafani, Francesco (2021) 2021 ASCO Annual Meeting I —
    • Journal article
    Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer
    Bregni, Giacomo Vandeputte, Caroline Pretta, Andrea Senti, Chiara Trevisi, Elena Acedo Reina, Elena Kehagias, Pashalina Liberale, Gabriel Moretti, Luigi Bali, Maria Antonietta Demetter, Pieter Flamen, Patrick Carrasco, Javier D'Hondt, Lionel[UCL] Geboes, Karen Gokburun, Yeter Peeters, Marc Van den Eynde, Marc[UCL] Van Laethem, Jean-Luc Vergauwe, Philippe Chapot, Camille Anastasia Buyse, Marc Deleporte, Amelie Hendlisz, Alain Sclafani, Francesco (2021) Acta oncologica — Vol. 60, no. 4, p. 549-553 (2021)
    • Journal article
    Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
    Kelly, Ronan J Ajani, Jaffer A Kuzdzal, Jaroslaw Zander, Thomas Van Cutsem, Eric Piessen, Guillaume Mendez, Guillermo Feliciano, Josephine Motoyama, Satoru Lièvre, Astrid Uronis, Hope Elimova, Elena Grootscholten, Cecile Geboes, Karen Zafar, Syed Snow, Stephanie Ko, Andrew H Feeney, Kynan Schenker, Michael Kocon, Piotr Zhang, Jenny Zhu, Lili Lei, Ming Singh, Prianka Kondo, Kaoru Cleary, James M Moehler, Markus CheckMate 577 Investigators Van den Eynde, Marc[UCL] (2021) The New England journal of medicine — Vol. 384, no.13, p. 1191-1203 (2021)
    • Journal article
    The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis.
    Repullo, Deborah J Barbois, Sandrine[UCL] Léonard, Daniel[UCL] Bohlok, Ali Van den Audenaeren, Estelle T Hendlisz, Alain Van den Eynde, Marc[UCL] Donckier, Vincent Kartheuser, Alex[UCL] Liberale, Gabriel (2021) European Journal of Surgical Oncology — Vol. 47, no. 7, p. 1661-1667 (2021)
    • Speech
    394P Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34-FFCD 1402-ADAGE randomized phase III trial
    Aparicio, T. Bouche, O. Etienne, P.L. Barbier, E. Mineur, L. Desgrippes, R. Hocine, F. Martin, J.J. Lebrun-Ly, V. Crétin, J. Desrame, J. Rinaldi, Y. Cany, L. Falandry, C. Terrebonne, E. Mosser, L. Pauwels, M. Turpin, A. Van den Eynde, Marc[UCL] Hiret, S. (2021) —
    • Journal article
    Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore.
    Baldin, Paméla[UCL] Van den Eynde, Marc[UCL] Mlecnik, Bernhard Bindea, Gabriela Beniuga, Gabriela Carrasco, Javier Haicheur, Nacilla Marliot, Florence Lafontaine, Lucie Fredriksen, Tessa Lanthier, Nicolas[UCL] Hubert, Catherine[UCL] Navez, Benoît[UCL] Huyghe, Nicolas[UCL] Pagès, Franck Mourin, Anne[UCL] Galon, Jérôme Komuta, Mina[UCL] (2021) The journal of pathology. Clinical research — Vol. 7, no. 1, p. 27-41 (2021)
    • Speech
    505TiP REGINA: A phase II trial of neoadjuvant regorafenib (rego) in combination with nivolumab (nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC)
    Bregni, G. Senti, C. Reina, E. Acedo Gkolfakis, P. Moretti, L. Veron, A. Demetter, P. Liberale, G. Carrasco, J. Geboes, K. Gokburun, Y. Peeters, M. Van den Eynde, Marc[UCL] Laethem, J-L. van Vergauwe, P. Buyse, M.E. Deleporte, A. Hendlisz, A. Sclafani, F. (2021) ESMO 2021 —
    • Speech
    397P R-IMMUNE interim analysis: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with localized rectal cancer
    Carrasco, J. Schröder, D. Sinapi, I.[UCL] De Cuyper, Astrid[UCL] Beniuga, G. Delmarcelle, S. Laethem, J-L. van Huyghe, N. Bar, I. Hendlisz, A. Haustermans, K.M. Delaunoit, T. Coche, J-C. Van Ooteghem, Geneviève[UCL] Boulanger, A-S. Baldin, Paméla[UCL] Van den Eynde, Marc[UCL] (2021) ESMO 2021 —
    • Journal article
    Prediction of tumor response and patient outcome after radioembolization of hepatocellular carcinoma using 90Y-PET-computed tomography dosimetry.
    D'Abadie, Philippe[UCL] Walrand, Stephan[UCL] Hesse, Michel[UCL] Annet, Laurence[UCL] Borbath, Ivan[UCL] Van den Eynde, Marc[UCL] Lhommel, Renaud[UCL] Jamar, François[UCL] (2021) Nuclear medicine communications — Vol. 42, no. 7, p. 747-754 (2021)
    • Journal article
    Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy
    Lauret Marie Joseph, Elodie Kirilovsky, Amos Lecoester, Benoît El Sissy, Carine Boullerot, Laura Rangan, Laurie Marguier, Amélie Tochet, Florent Dosset, Magalie Boustani, Jihane Ravel, Patrice Boidot, Romain Spehner, Laurie Haicheur-Adjouri, Nacilla Marliot, Florence Pallandre, Jean-René Bonnefoy, Francis Scripcariu, Viorel Van den Eynde, Marc[UCL] Cornillot, Emmanuel Mirjolet, Céline Pages, Franck Adotevi, Olivier (2021) Journal for immunotherapy of cancer — Vol. 9, no. 7, p. e002256 [1-17] (2021)
    • Journal article
    Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.
    Deleporte, Amélie Van den Eynde, Marc[UCL] Forget, Frédéric Holbrechts, Stéphane Delaunoit, Thierry Houbiers, Ghislain Kalantari, Hassan R Laurent, Stéphanie Vanderstraeten, Erik De Man, Marc Vergauwe, Philippe Clausse, Marylene Van Der Auwera, Jacques D'Hondt, Lionel[UCL] Pierre, Pascal Ghillemijn, Bjorn Covas, Angelique Paesmans, Marianne Ameye, Lieveke Awada, Ahmad Sclafani, Francesco Hendlisz, Alain (2021) Cancer medicine — Vol. 10, no. 13, p. 4366-4374 (2021)
    • Journal article
    Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
    Mansoor, Wasat Arkenau, Hendrik-Tobias Alsina, Maria Shitara, Kohei Thuss-Patience, Peter Cuffe, Sinead Dvorkin, Mikhail Park, David Ando, Takayuki Van den Eynde, Marc[UCL] Beretta, Giordano D Zaniboni, Alberto Doi, Toshihiko Tabernero, Josep Ilson, David H Makris, Lukas Benhadji, Karim A Van Cutsem, Eric (2021) Gastric cancer — Vol. 24, no. 4, p. 970-977 (2021)